Selected Stock Price Target News of the Day — June 4, 2026

Today’s stock price target news covers three high-volume analyst stories on June 4, 2026. CrowdStrike Holdings produced a wave of price target increases after its Q1 FY27 earnings beat. The report exceeded Wall Street expectations on every key metric. Veeva Systems reported its own quarterly results and split the analyst community between firm bulls and sharp-cutting bears. UnitedHealth Group earned a fresh Buy upgrade from BofA Securities on improving fundamentals. Here is the full analyst breakdown.

CrowdStrike Holdings ($CRWD): A Stock Price Target News Wave After Q1 Earnings

CrowdStrike Holdings (CRWD) reported Q1 fiscal year 2027 earnings on June 3, 2026. The results landed above analyst expectations on net new annual recurring revenue. Management raised full-year ARR guidance by an amount that exceeded the Q1 beat itself. That combination drove nine firms to raise price targets on the same morning, and a tenth to reiterate an above-consensus target. A strong quarter followed by a larger-than-expected guidance raise is rare in this market. Every action was a raise or a reiteration of an above-consensus target. Not one firm cut.

The largest single-session move came from Mike Cikos at Needham. Cikos raised his price target from $475 to $780. That is a 64% increase in his conviction number in one session. He maintained his Buy rating. Cikos carries a 64.28% price target hit rate on AnaChart. His average upside of 18.43% has been achieved within 118 days historically. His prior $475 target had already reflected confidence in CrowdStrike’s AI product transition. The new $780 target signals that the transition is arriving faster than even the bulls projected.

Adam Borg at Stifel raised his target from $660 to $790. That is the highest published price target on CrowdStrike today. Borg maintained his Buy rating. He cited accelerating adoption of Falcon Flex, CrowdStrike’s consumption-based licensing model, as the primary driver of the Q1 revenue beat. Falcon Flex allows enterprise customers to expand usage without restarting a procurement cycle. That model is driving faster platform consolidation across CrowdStrike’s largest accounts.

Tal Liani at BofA Securities raised his target from $535 to $750. The 40% increase reflects a meaningful revision to Liani’s long-term model. He maintained his Buy rating. Liani has tracked CrowdStrike through multiple product cycles. He views the company’s April “Mythos” AI platform announcement as the commercial inflection point now showing up in pipeline data. The AIDR module, launched as part of the Mythos release, is generating commercial traction ahead of initial projections.

Junaid Siddiqui at Truist Securities raised his target from $650 to $750. He maintained his Buy rating. Siddiqui described Q1 as “a strong start to FY27.” He noted that full-year net new ARR guidance was raised by a magnitude that exceeded the Q1 beat. Jonathan Ruykhaver at Cantor Fitzgerald raised from $700 to $725. Gray Powell at BTIG reiterates his Buy rating and holds his $764 target. Additional raises this morning came from Citizens ($780), Canaccord ($675), Mizuho ($700), and Baird ($520).

CrowdStrike operates the Falcon platform as a unified intelligence layer spanning identity, endpoint, and cloud security. AIDR extends Falcon into autonomous detection and response. CrowdStrike’s current trading price sits near $747, making Stifel’s $790 target roughly 6% above the last close. Tracked analysts show 44 Buy ratings, 13 Holds, and 2 Sells on CrowdStrike. The consensus direction remains firmly bullish heading into Q2.

Veeva Systems ($VEEV): Stock Price Target News Splits Analysts After Q1 Report

Veeva Systems (VEEV) reported Q1 FY27 results that satisfied some analysts and fell short for others. The quarter showed solid performance in Veeva’s commercial cloud business. It did not deliver the CRM migration acceleration that bears needed to change their stance. The result is a bimodal analyst distribution with one of the widest published PT spreads of this earnings cycle.

David Larsen at BTIG holds the highest price target on Veeva at $340. He reiterates his Buy rating without modification. Larsen views Veeva as structurally well-positioned for life sciences CRM consolidation over a multi-year horizon. Near-term revenue timing is secondary to that thesis. Larsen has covered Veeva through several transitions and consistently applies a long-duration framework to his valuation.

Ryan MacDonald at Needham reiterates his Buy rating at a $270 price target. MacDonald’s note described Veeva as “remains well-positioned in the long-term.” Both BTIG and Needham are holding their targets unchanged. That is a signal of conviction rather than complacency. Neither analyst saw a reason in Q1 to raise the bar, but neither saw a reason to lower it either.

Stan Berenshteyn at Wells Fargo raised his target from $317 to $320. The $3 increase is directionally positive but operationally nominal. Berenshteyn maintained his current rating.

The bear case on Veeva is anchored by Goldman Sachs analyst Adam Hotchkiss, who cut his target to $165. That is the lowest published price target on Veeva from any covered firm today. It sits more than 50% below BTIG’s $340. Hannah Rudoff at Piper Sandler cut from $285 to $235 while maintaining her Overweight rating. Rudoff trimmed her expectations for near-term CRM migration velocity. Evercore ISI cut to $185. Stifel lowered to $230. Raymond James reduced to $225. Barclays cut to $235. Goldman Sachs stands at the low end at $165.

The spread between the highest published target ($340 from BTIG) and the lowest ($165 from Goldman Sachs) exceeds 100%. Most stock coverage disagreements fall in the 15 to 25% range. This gap reflects genuine disagreement on timing rather than direction. The bull case requires Veeva’s life sciences clients to accelerate CRM platform migration within the next two to three quarters. The bear case assumes that timeline extends into FY28 or beyond, compressing near-term revenue growth below consensus models.

UnitedHealth Group ($UNH): BofA Securities Issues Buy Upgrade

UnitedHealth Group (UNH) earned a clean upgrade this morning. Kevin Fischbeck at BofA Securities upgraded UnitedHealth from Neutral to Buy. He raised his price target from $420 to $450. Fischbeck carries a 68.43% price target hit rate on AnaChart, with an average upside of 25.33% achieved within 253 days.

The upgrade reflects Fischbeck’s view that UnitedHealth’s headwinds are now priced into the stock. The company has navigated a difficult environment in 2026. Elevated medical cost ratios weighed on margins in the first part of the year. Regulatory pressure on Medicare Advantage reimbursement rates created additional uncertainty. Fischbeck’s note argues that those risks are now sufficiently reflected in UnitedHealth’s current valuation. His $450 target implies roughly 7% upside from the prior close.

UnitedHealth operates two primary segments. UnitedHealthcare is the core insurance arm, covering commercial, Medicare Advantage, and Medicaid populations. Optum is the health services division, which includes pharmacy benefit management, primary care clinics, and health data analytics. Optum’s operating margins are structurally higher than UnitedHealthcare’s. Fischbeck’s upgrade applies to the consolidated entity. His thesis requires margin recovery in the UnitedHealthcare segment by year-end.

The full price target history for CrowdStrike, Veeva Systems, and UnitedHealth Group, along with the track record of every analyst and firm named here, lives in the analyst price target dataset. It covers 661,383 price targets and 759,654 ratings from 7,191 analysts (3,754 active, 3,437 retired), across 9,686 tickers and 424 brokers (333 active), spanning 2008 to 2026.